Abstract
Fluoroquinolones (FQ) are an important family of synthetic antimicrobial agents being clinically used over the past thirty years. Currently some FQ are under investigation for the treatment of multidrug-resistant tuberculosis (MDRTB), defined as resistance to at least isoniazid and rifampicin, and are under investigation as first-line drugs. Their main biological target in Mycobacterium tuberculosis is the DNA gyrase, a topoisomerase II encoded by gyrA and gyrB that is essential to maintain the DNA supercoil. It has been demonstrated that mutations in short regions of DNA gyrase are associated with quinolone resistance or hypersusceptibility and take place in several MDR clinical isolates of M. tuberculosis. In this article we update§ our previous review (Carta et al. Anti-infective agents, 2008, 7, 134-147) about the anti mycobacterial properties, mode of action and structure activity relationship (SAR) studies of the known quinolone derivatives. Furthermore, we update the synthesis and activity of 3,9-disubstituted-6-oxo-6,9-dihydro-3H-[1,2,3]-triazolo[4,5-h,g]quinolonecarboxylic acids and their esters as a new class of potent and selective anti-mycobacterial agents, coupled with absence of cytotoxicity. Furthermore, particularly interesting is their activity against MDR M. tuberculosis.
Keywords: Anti-mycobacterial activity, DNA gyrase inhibitors, MDR-TB, quinolones, SAR analysis, triazoloquinolones antitubercular activity.
Anti-Infective Agents
Title:SAR and Anti-Mycobacterial Activity of Quinolones and Triazoloquinolones: An Update
Volume: 11 Issue: 1
Author(s): Irene Briguglio, Sandra Piras, Paola Corona, Maria A. Pirisi, Daniela Jabes and Antonio Carta
Affiliation:
Keywords: Anti-mycobacterial activity, DNA gyrase inhibitors, MDR-TB, quinolones, SAR analysis, triazoloquinolones antitubercular activity.
Abstract: Fluoroquinolones (FQ) are an important family of synthetic antimicrobial agents being clinically used over the past thirty years. Currently some FQ are under investigation for the treatment of multidrug-resistant tuberculosis (MDRTB), defined as resistance to at least isoniazid and rifampicin, and are under investigation as first-line drugs. Their main biological target in Mycobacterium tuberculosis is the DNA gyrase, a topoisomerase II encoded by gyrA and gyrB that is essential to maintain the DNA supercoil. It has been demonstrated that mutations in short regions of DNA gyrase are associated with quinolone resistance or hypersusceptibility and take place in several MDR clinical isolates of M. tuberculosis. In this article we update§ our previous review (Carta et al. Anti-infective agents, 2008, 7, 134-147) about the anti mycobacterial properties, mode of action and structure activity relationship (SAR) studies of the known quinolone derivatives. Furthermore, we update the synthesis and activity of 3,9-disubstituted-6-oxo-6,9-dihydro-3H-[1,2,3]-triazolo[4,5-h,g]quinolonecarboxylic acids and their esters as a new class of potent and selective anti-mycobacterial agents, coupled with absence of cytotoxicity. Furthermore, particularly interesting is their activity against MDR M. tuberculosis.
Export Options
About this article
Cite this article as:
Briguglio Irene, Piras Sandra, Corona Paola, A. Pirisi Maria, Jabes Daniela and Carta Antonio, SAR and Anti-Mycobacterial Activity of Quinolones and Triazoloquinolones: An Update, Anti-Infective Agents 2013; 11 (1) . https://dx.doi.org/10.2174/22113626130109
DOI https://dx.doi.org/10.2174/22113626130109 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bicyclic 6 + 6 Systems: Advances in the Chemistry of Heterocyclic Compounds Incorporated Pyrimido[1,2-a]Pyrimidine Skeleton
Mini-Reviews in Organic Chemistry Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Design and Synthesis of Some Newer Pyrimidine Hydroxamates as Histone Deacetylase Inhibitors
Current Enzyme Inhibition Synthesis of Bicyclic Aryl Thiazolines with Selective Anti-Proliferative Effects on Human Cancer Cell Lines
Letters in Organic Chemistry Fluoroquinolones: Blessings Or Curses
Current Drug Targets New Potential Pharmaceutical Applications of Hypericum Species
Mini-Reviews in Medicinal Chemistry Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Isoniazid is Not a Lead Compound for its Pyridyl Ring Derivatives,Isonicotinoyl Amides, Hydrazides, and Hydrazones: A Critical Review
Current Medicinal Chemistry The Methylerythritol Phosphate Pathway and its Significance as a Novel Drug Target
Current Pharmaceutical Biotechnology Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding
Current Topics in Medicinal Chemistry Intestinal Fibrosis in Crohns Disease: Medical Treatment or Surgery?
Current Drug Targets Key Sites for P2X Receptor Function and Multimerization: Overview of Mutagenesis Studies on a Structural Basis
Current Medicinal Chemistry A Guide to Treatment of Sarcoidosis
Current Drug Therapy Targeting Intracellular Targets
Current Drug Delivery Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery The Significant Role of Nutraceutical Compounds in Ulcerative Colitis Treatment
Current Medicinal Chemistry Editorial (Thematic Issue: Recent Trends in Library Design and Virtual Screening in Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry HLA-E and HLA-E-Bound Peptides: Recognition by Subsets of NK and T Cells
Current Pharmaceutical Design Crystal Structure of a Flavin-dependent Thymidylate Synthase from Helicobacter pylori strain 26695
Protein & Peptide Letters Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets